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Objective. Tranexamic acid (TXA) is increasingly used in orthopedic surgery to reduce blood loss; however, there are concerns
about the risk of venous thromboembolic (VTE) complications. The aim of this study was to evaluate TXA safety in patients
undergoing lower limb orthopedic surgical procedures. Design. A meta-analysis was performed on the PubMed, Web of Science,
and Cochrane Library databases in January 2020 using the following string (Tranexamic acid) AND ((knee) OR (hip) OR
(ankle) OR (lower limb)) to identify RCTs about TXA use in patients undergoing every kind of lower limb surgical orthopedic
procedures, with IV, IA, or oral administration, and compared with a control arm to quantify the VTE complication rates.
Results. A total of 140 articles documenting 9,067 patients receiving TXA were identified. Specifically, 82 studies focused on
TKA, 41 on THA, and 17 on other surgeries, including anterior cruciate ligament reconstruction, intertrochanteric fractures,
and meniscectomies. The intravenous TXA administration protocol was studied in 111 articles, the intra-articular in 45, and the
oral one in 7 articles. No differences in terms of thromboembolic complications were detected between the TXA and control
groups neither in the overall population (2.4% and 2.8%, respectively) nor in any subgroup based on the surgical procedure and
TXA administration route. Conclusions. There is an increasing interest in TXA use, which has been recently broadened from the
most common joint replacement procedures to the other types of surgeries. Overall, TXA did not increase the risk of VTE
complications, regardless of the administration route, thus supporting the safety of using TXA for lower limb orthopedic
surgical procedures.
1. Introduction
Lower limb procedures represent the majority of orthopedic
surgeries, including joint arthroplasties, sport medicine treat-
ments, and fracture osteosynthesis, with a high rate of over
500 per 100,000 population every year, increasing over time
[1, 2]. Among these, total hip arthroplasty (THA) and total
knee arthroplasty (TKA) are the most commonly performed.
Albeit being successful procedures routinely performed in
the clinical practice, they are frequently encumbered by
complications [3]. In particular, joint arthroplasties are often
associated with a significant amount of postoperative blood
loss, ranging from 800 to 1,800ml in primary TKA or THA,
with up to 25% and 37% of patients, respectively, requiring
blood transfusion for postoperative anemia [4, 5]. Allogenic
blood transfusions are financial burdens, and even more
importantly, they are associated with an unneglectable risk
of serious complications, including infection, immunosup-
pression, and cardiovascular dysfunction [6], resulting in
potentially life-threatening effects on patients [7]. Various
strategies have been attempted to minimize blood loss and
the need for blood transfusion [8], and to this aim, the use of
hemostatic agents, in particular of tranexamic acid (TXA),
has recently widely increased in orthopedic lower limb surgery.
TXA is a synthetic antifibrinolytic agent that competi-
tively blocks the lysine binding sites on plasminogen, thereby
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slowing the conversion of plasminogen to plasmin, thus pre-
venting fibrin clot degradation [9, 10]. A large amount of
randomized controlled trials (RCTs) and high-level evidence
[11–14] converges in showing that TXA, applied either
through systemic or local administration, is effective in
reducing blood loss and subsequent transfusions in replace-
ment procedures, as well as in other kinds of lower limb
surgeries, including sport medicine procedures and fracture
treatment [15, 16]. However, there are still concerns about
the risk of increasing venous thromboembolic (VTE) com-
plications, such as deep venous thrombosis (DVT) or pulmo-
nary embolisms (PE) [17, 18]. In this light, it is of paramount
importance to understand if the scientific high-level litera-
ture evidence supports the safety of TXA for the different
orthopedic applications.
Thus, the aim of this study was to evaluate, through a
meta-analysis of RCTs, the safety of TXA used in patients
undergoing lower limb orthopedic surgical procedures,
including joint arthroplasty, fracture treatment, and sport
injuries.
2. Material and Methods
2.1. Search Strategy and Article Selection.Ameta-analysis was
performed based on the literature evidence about the throm-
boembolic complications of TXA in patients undergoing
orthopedic lower limb surgery. The search was conducted
on the PubMed, Web of Science, and Cochrane Library data-
bases on January 9, 2020, using the following parameters:
(Tranexamic acid) AND ((knee) OR (hip) OR (ankle) OR
(lower limb)). The guidelines for Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) were
used [19]. A flowchart of the study selection for the quantita-
tive data synthesis is reported in Figure 1.
The screening process and analysis were conducted sepa-
rately by 2 independent observers (DR and SG). In the first
step, the articles were screened by title and abstract. The fol-
lowing inclusion criteria for relevant articles were used dur-
ing the initial screening of titles and abstracts: RCTs,
written in the English language, and about TXA use in
patients undergoing every kind of lower limb surgical ortho-
pedic procedure. Exclusion criteria were articles written in
other languages, preclinical studies, studies of a different
design than RCT, and reviews. No exclusions were made
regarding the administration route (intra-articular (IA),
intravenous (IV), and oral), dose (dosage amount and bolus
versus continuous infusion), and timing of administration
(preoperative, intraoperative, or postoperative).
In the second step, the full texts of the selected articles
were retrieved and screened, with the further exclusion of
RCTs without at least one treatment group receiving TXA
and a control group, either receiving placebo or not. For
example, surveys that had multiple treatment arms with
other antifibrinolytic agents such as epsilon aminocaproic
acid (EACA) were eligible, but only if they also analyzed sep-
arately one treatment arm with TXA and one control arm,
with only TXA and control groups being included in the
analysis. Moreover, studies not addressing the occurrence
of VTE complications were excluded. No limitations were
set based on the postoperative VTE chemoprophylaxis or
on the method of screening or diagnosis for VTE used in each
study. Reference lists from the selected papers were also
screened, and all selected studies were included in the quan-
titative data synthesis.
2.2. Data Extraction, Outcome Measurement, and Statistical
Analysis. The following information on trial methodology
and included patients were extracted and collected in a data-
base with the consensus of the two observers: publication
year, study design, number of patients included, type of sur-
gery, route of administration of TXA, and number of VTE
complications to the purpose of this study. Accordingly, a
meta-analysis on the VTE complication rate of the studies
included was performed.
The statistical analysis and the forest plot were carried
out according to Neyeloff et al. [20] using Microsoft Excel.
The dichotomous outcome was a rare event, and most of
the articles compared groups of similar dimensions and
showed zero events, so Peto’s method (Yusuf 1985 and
Bradburn 2007) was used to provide a pooled odds ratio;
the reason for the choice was that Peto’s method does not
need the corrections for zero cell counts. The statistical sig-
nificance was based on the z statistics of Peto’s estimation
of the pooled odds ratio. p value of 0.05 was used as the level
of statistical significance.
3. Results
The database search retrieved 1,797 records; out of these, 140
articles [11, 12, 15, 16, 21–157] were eligible for the meta-
analysis of VTE (Figure 1). The publication trend showed
that the majority of these RCTs were published in the last five
years: 46% from 1996 to 2015 and 54% after 2015 (Figure 2).
Overall, 9,067 patients received TXA while 6,592 were
included in the control groups. With regard to the type of
surgery, 82 studies [21–24, 26–28, 30, 31, 34–38, 40, 45, 47,
49–51, 55–58, 60, 61, 63, 65, 66, 70, 72, 73, 75, 76, 78–82,
84, 85, 87, 88, 90, 92, 93, 96, 98, 99, 104–111, 113, 114,
117–119, 121, 123, 124, 126–128, 130, 134–137, 140–142,
146, 147, 151, 153, 154, 156] (5,267 cases and 3,498 controls)
were focused on TKA, 41 studies [11, 12, 25, 32, 33, 42–44,
48, 52–54, 62, 64, 67–69, 74, 77, 79, 83, 88, 89, 94, 101–103,
116, 122, 125, 129, 131–133, 138, 139, 143, 144, 148, 150,
152] (2,655 cases and 1,941 controls) on THA, and 17 studies
[15, 16, 39, 41, 46, 59, 71, 86, 91, 95, 112, 115, 120, 145, 149,
155, 157] (1,025 cases and 1,035 controls) on other lower
limb surgeries. Four articles analyzed both TKA and THA:
two of them [79, 88] reported separately VTE complications
for TKA and THA and thus were considered in each type of
surgery group; conversely, the other two [97, 100] did not
report separately VTE complications and thus were not allo-
cated in any group. The administration protocol of TXA
included 3 types of administration routes: IV (111 studies,
5,599 cases and 4,980 controls), IA (45 studies, 2,756 cases
and 2,495 controls), and oral (7 studies, 712 cases and 362
controls). Studies applying a combination of modalities were
included only in the largest group according to the following
order: IV>IA>oral. All modalities (dosage amount and bolus
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versus continuous infusion) and timing (preoperative, intra-
operative, or postoperative) of TXA administration were
included without further selection.
The quantitative analysis on VTE was first performed
and reported on the total of the studies included, then sepa-
rately for TKA, THA, and other orthopedic surgical proce-
dures of the lower limb. Moreover, a subanalysis for the
different administration routes (IV, IA, and oral) with
enough available studies reporting VTE was performed.
3.1. Total Lower Limb Orthopedic Surgical Procedures.
Among 140 high-level RCTs, including 9,067 patients receiv-
ing TXA and 6,592 controls, no significant difference in the
occurrence of thromboembolic complications between the
two groups was detected, with a total VTE rate of 2.4% and
2.8% for TXA and controls, respectively (OR 0.91 [95% CI
0.76-1.09]; p = 0:291). With regard to the administration
route, the 111 RCTs [12, 15, 16, 21, 22, 26, 30–35, 37–40,
42–45, 47–55, 57, 59–64, 66–68, 70–87, 89–95, 97–100, 103,
105–150, 152–157] comparing IV TXA versus controls, on
5,599 and 4,980 patients, respectively, reported a rate of
VTE equal to 2.7% and 2.6%, respectively (OR 0.96 [95%
CI 0.77-1.20]; p = 0:709). The 45 RCTs [11, 21, 24, 25, 27,
28, 36, 41, 45–47, 56, 58, 65, 69, 75, 79–81, 88, 96, 99, 101,
102, 104–108, 117, 118, 123, 126, 127, 129–132, 134–137,
139, 140, 144] comparing IA TXA administration (2,756
patients) and controls (2,495 patients) reported a rate of
VTE of 2.3% and 2.8%, respectively (OR 0.84 [95% CI 0.60-
1.17]; p = 0:307). Only 7 studies [23, 124, 125, 136, 143,
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Figure 2: Publications’ trend of RCTs about tranexamic acid in
orthopedic lower limb surgery from 1995 to 2020.
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patients) and controls (362 patients), reporting a rate of
1.0% and 2.8%, respectively (OR 0.66 [95% CI 0.28-1.58];
p = 0:391).
3.2. Total Knee Arthroplasty. The analysis of the 82 RCTs on
TKA showed a total of 5,267 patients belonging to the TXA
group with 164 VTE and 3,498 patients of the control group
with 135 VTE, without any significant difference in terms of
VTE complications, being 3.1% and 3.9%, respectively (OR
0.86 [95% CI 0.70-1.07]; p = 0:189). Among 62 RCTs com-
paring 3,122 TXA administered IV to 2,687 controls, the
number of VTE complications was 105 and 90, respectively,
with a corresponding equal VTE rate of 3.4% (OR 0.92
[95% CI 0.70-1.21]; p = 0:549). Analogously, the meta-
analysis of the 33 studies about IA TXA administration
showed no significant difference for the VTE rate (1,713
out of 3,178 patients) compared to the control group (1,465
out of 3,178 patients), being 3.0% and 4.1%, respectively
(OR 0.81 [95% CI 0.56-1.17]; p = 0:268) (Figure 3).
3.3. Total Hip Arthroplasty. Regarding THA, a total of 41
studies with 2,655 patients belonging to the TXA group and
1,941 patients to the control group reported 30 and 21
VTE, respectively, without any significant difference in terms
of VTE complications, being 1.1% in both groups (OR 1.07
[95% CI 0.67-1.70]; p = 0:769). Among the 33 RCTs compar-
ing TXA (1,583 patients) administered IV to controls (1,389
patients), the rates of VTE were 1.4% and 1.2%, respectively
(OR 1.09 [95% CI 0.63-1.89]; p = 0:749). Similarly, the
meta-analysis of 12 studies on IA TXA showed no significant
difference in the VTE rate compared to controls, being 1.0%
and 0.9%, respectively (OR 1.09 [95% CI 0.44-2.68]; p =
0:857) (Figure 4).
3.4. Other Lower Limb Orthopedic Surgical Procedures.
Among the 17 RCTs on the patients undergoing other lower
limb surgical procedures, including intertrochanteric frac-
tures (13 studies, 763 cases and 771 controls), meniscec-
tomies (1 study, 18 cases and 23 controls), and ACL
reconstructions (3 studies, 244 cases and 241 controls),
1,025 patients were included in the TXA group and 1,035
in the control group, reporting a similar total rate of VTE
of 2.6% and 2.4%, respectively (OR 1.06 [95% CI 0.63-1.77];
p = 0:827). Regarding the IV administration group, the
meta-analysis of 15 studies had a similar rate of VTE in the
774 patients with TXA compared to 786 controls, being
3.1% and 2.7%, respectively (OR 1.11 [95% CI 0.64-1.93];
p = 0:712) (Figure 5).
4. Discussion
The main finding of this RCT meta-analysis was that TXA
did not increase the risk of VTE complications in patients
undergoing lower limb orthopedic surgery. This finding
remained consistent for patients undergoing both THA and
TKA and other lower limb surgical procedures, as well as
for different TXA administration routes (IV, IA, and oral).
TXA was introduced in the clinical practice as a synthetic
antifibrinolytic agent aiming at reducing intra- and postoper-
ative blood loss. This represents one of the most common
complications associated with major orthopedic surgeries
resulting in increased impairment of functional ability, lon-
ger hospitalization, and increased morbidity and mortality
[158]. Allogenic transfusions are often used to address post-
operative anemia and its detrimental consequences, but they
are not free from serious adverse events. Accordingly, TXA
has been increasingly employed in recent years in replace-
ment surgery of the lower limb joints, and now plenty of
high-level studies regarding RCTs and meta-analyses have
been published, demonstrating its effectiveness in reducing
blood loss and consequently the need for postoperative trans-
fusions [159, 160]. Among these, in 2015, Wu et al. [159]
published a meta-analysis on 34 studies and reported that
IV or IA use of TXA significantly reduced the postoperative
blood loss, hemoglobin decrease, and transfusion rate after
primary TKA, though without reducing intraoperative blood
loss. Similarly, in the same year, Wei and Liu [160] analyzed
39 trials, confirming that the administration of TXA signifi-
cantly reduced blood loss and the need for allogeneic blood
transfusion. In light of such promising results, the use of
TXA has been recently extended also to other lower limb pro-
cedures, such as ACLR andmeniscectomies, where the aim of
TXA, in addition to reducing perioperative blood loss, is to
improve early functional recovery. Promising results have
been shown also for these indications, with a significant
reduction of hemarthrosis and the amount of suction drain-
age blood volume, as well as improved ROM and quadriceps
strength and a lower rate of fever during the first 2 weeks
after surgery [15]. Despite the positive findings of these
recent attempts to broaden the application of TXA in
orthopedic surgery, there are still concerns about its use
among orthopedic surgeons and anesthesiologists regard-
ing its safety, in particular the possible increased risk of
VTE [17, 18].
In the current study, a meta-analysis was performed to
quantify the complication rate reported for TXA compared
to controls in high-level trials. In these studies, TXA was used
for the intra- and postoperative blood loss management in
TKA and THA and also in other lower limb surgical proce-
dures, such as ACLR, meniscectomies, and intertrochanteric
fractures. Based on this meta-analysis of 140 RCTs, including
15,659 patients, no significant differences were found in the
occurrence of VTE between TXA and controls, with a total
rate of 2.4% and 2.8%, respectively. Furthermore, included
patients were grouped according to the type of surgery
(TKA, THA, and other procedures) and to the method of
administration (IV, IA, and oral) in order to investigate pos-
sible differences in the complication risk in the different sub-
groups. The subanalysis confirmed no significant differences
in terms of the VTE rate, demonstrating the safety of TXA
administration for all these surgical procedures regardless
of the administration route, either IV, IA, or oral.
Interestingly, the rate of VTE observed in THA, close to
1%, was lower compared to the 3% reported in TKA, and this
difference was consistent in both the TXA and control
groups. A possible explanation of this lower VTE rate in
THA compared to TKA could be traced back to different
rehabilitation protocols with earlier weight bearing and the
different applications of cement and tourniquet [161–163].
4 BioMed Research International
Nevertheless, a strong statistical methodology could be
applied to the selected papers only to detect any possible dif-
ferences between TXA and controls in the different proce-
dures, while it was not possible to perform an indirect
comparative analysis of different subgroups according to
the specific surgery. Similarly, it was not possible to compare
subgroups differing in terms of administration routes within
TXA and control groups. However, this aspect has been
already investigated in other studies, which have suggested
superior safety of topical application of TXA compared with
IV application of TXA, based on the finding that topically
applied TXA results in a 90% reduction in plasma concentra-
tion compared to IV [164]. What was instead proven with
robust statistical analysis of high-level trials, all directly com-
paring TXA and control groups, was that both the IV admin-
istration and the IA administration of TXA did not increase
the risk of thromboembolic events compared to controls,
regardless of the joint or the surgery considered.
While many literature analysis attempts were focused on
the effects of TXA in terms of blood loss reduction, only a few
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Figure 3: Forest plot of the 82 studies comparing the VTE rate between the TXA group and the control group for TKA. Point estimates of the
weighted odds ratios for each study are represented by squares, and the 95%CIs are represented by horizontal bars. The summary odds ratio is
represented by a black diamond.
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studies specifically addressed the possible complications
[165, 166]. Fillingham et al. [165] performed a meta-
analysis on 78 studies focusing only on joint replacement
procedures, including patients exclusively undergoing joint
arthroplasty, published up to 2017, reporting that TXA was
not associated with an increased risk of VTE also in “high-
risk” patients ASA ≥ 3 undergoing TKA. Likewise, in the
same year, Franchini et al. [166] concluded that TXA is a safe
pharmacological treatment after a meta-analysis on 73 RCTs
focused only on IV administration in patients undergoing
joint replacements or hip fracture management.
The current analysis included the latest high-level evi-
dence quantifying the VTE risks considering all types of
lower limb orthopedic surgeries and all TXA administration
routes, not considered in the previous studies, which allowed
to further corroborate the TXA safety and extend the inter-
pretation of existing data to a broader scenario of clinical
applications. This is of particular importance since the com-
plications of each application should be weighted with the
respective expected benefits. In fact, while joint replacement
procedures entail high risks of blood loss, which justifies
the potential risk of using drugs to reduce blood loss, an
increased VTE risk would be less justified in other proce-
dures, where the expected benefit is mainly in terms of faster
recovery. In this light, the results of the meta-analysis about
patients undergoing ACLR, intramedullary nailing for femo-
ral fractures and meniscectomies, are of importance. In par-
ticular, the results confirm no difference in terms of the
VTE rate for patients treated with TXA compared to con-
trols, thus supporting its use also for these new indications,
which are increasingly explored in both the literature and
the clinical practice.
The large number of high-level trials included in this
meta-analysis assures the most reliable methodology to syn-
thesize the scientific evidence about complications related
to the use of TXA in lower limb orthopedic surgeries. How-
ever, this study still presents several limitations. First, it must
be underlined that the included studies are heterogeneous
with regard to TXA dosing and timing of administration.
Moreover, different VTE screening methods were applied
in the different studies, and also antithrombotic prophylaxis
regimens were not consistent among the included studies.
On the other side, the same methods were used within each
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RCT. Moreover, other studies demonstrated no effect on the
risk of VTE in patients under antithrombotic treatment who
received TXA during surgery, regardless of the type of anti-
thrombotic prophylaxis, thus not affecting the conclusions
of this study [130, 165]. Another limitation may be repre-
sented by the analysis only of VTE complications, although
this focus was necessary due to the available data. In fact,
albeit including a large number of patients, the low frequency
of other complications, such as infections, made it not possi-
ble to evaluate and compare them. Nevertheless, previous
studies did not suggest a higher infection risk when TXA is
applied, and in fact, TXA could rather reduce this kind of
complication since it was proved that the infection risk is
directly correlated with the number of allogeneic blood trans-
fusions administered [167, 168]. Further studies and large
registry analysis should investigate deeper these aspects.
Finally, the validity of the results regarding the safety of
TXA is limited to the patient categories defined by the inclu-
sion and exclusion criteria used in the published literature. In
fact, due to concerns about the administration of TXA in
high-risk patients, such as those with a history of thrombo-
embolic and ischemic events as well as vascular stents, these
types of patients were commonly excluded from RCTs. How-
ever, a recent study [165] suggested that patients with ASA
≥ 3 do not carry an increased risk of VTE with TXA admin-
istration, demonstrating the possibility to apply it also in
such challenging conditions.
Overall, this study not only confirms the safety of TXA
but also underlines the need to standardize the administra-
tion protocol (dosage, timing, and duration of administra-
tion) since great variability exists in the literature. This is
particularly important also in consideration of the heteroge-
neous applications documented in this meta-analysis, which
suggests the possibility to broaden the TXA indication also
to other surgeries than just joint arthroplasties, including
fractures and sport medicine procedures, supporting the
safety of using TXA for all lower limb orthopedic surgical
procedures.
5. Conclusions
This meta-analysis of TXA for lower limb orthopedic surgical
procedures showed an increasing interest over time, with
most of the articles published in the last 5 years. Moreover,
besides the most common applications for joint replacement
procedures, TXA use has been recently broadened to other
types of surgery. Overall, TXA did not increase the risk of
VTE complications. This finding remained consistent for
patients undergoing THA, TKA, and other lower limb surgi-
cal procedures, regardless of the administration route, thus
supporting the safety of using TXA for lower limb orthopedic
surgical procedures.
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